Abstract Aplastic anemia developed in 9 of 32 patients (28 percent) undergoing orthotopic liver trans· plantation for acute non·A, non-8 hepatitis, at one to seven weeks after the procedure. No patient previously had evidence of hematologic dysfunction or conditions known to be associated with aplastic anemia, No other cases of aplastic anemia were identified among 1463 patients undergoing liver transplantation for ali other indications at the four centers participating in the study (chi-square = 415, P<O.001; 95 percent confidence interval for the incidence of aplastic anemia aiter transplantation for non-A, non-8 hepatitis, 13 to 44 percent, vs, 0.00 to 0.13 percent for all other indications).
The operative and postoperative treatment of these patients was not otherwise different, indicating that the aplastic anemia was a complication of the hepatitis, not of the transplantation procedure. Four of the nine patients died of complications due to infections. Three of the surviving patients have been followed for less than six months, one for one year, and one for two years. The two patients followed the longest have recovered marrow function to an appreciable degree, and two of the others have evidence of early recovery,
We conclude that patients undergoing orthotopic liver transplantation for non-A, non-8 hepatitis are at a high riSk/ for the development of aplastic anemia. (N Engl J Med 1988; 319:393-6.) virus, cytomegalovirus, and herpes simplex virus was performed in all cases, Wilson's disease was diagnosed if low serum concentra· tions of ceruloplasmin and characteristic clinical findings were pres· ent, Non·A, non-B hepatitis was diagnosed if other causes of acute or subacute liver failure could be excluded.
Aplastic anemia was defined as a profound and protracted reduc· tion in the concentration of blood elements derived from the bone marrow, which required transfusion therapy and was related to marked hypoplasia or aplasia of the bone marrow. 5 ,6 Marrow samples were cultured for bacterial, fungal, and viral pathogens. Table I shows the characteristics of the nine patients in whom aplastic anemia developed. In each, the indication for transplantation was non-A, non-B hepatitis. All were in good health before the onset of hepatitis. None had a history of exposure to toxins, and none were receiving medication at the time of the onset of hepatitis.
REsULTS
The source of hepatitis was not evident in any of these patients. None had a history of exposure to hepatitis. Among the patients with non-A, non-B hepatitis who did not become anemic, several of the adult patients did have percutaneous exposure, and the sibling of one child subsequently had self-limited acute hepatitis. One patient (No.3) had an earlier episode of hepatitis without serologic markers, 11 months before the episode that led to transplantation.
The histopathological appearance of the liver specimens was consistent with severe viral hepatitis7; massive necrosis was observed in eight specimens, and submassive necrosis in one.
The hematologic values shown in Table 1 were those last obtained before transplantation. None of the patients had had prior episodes of prolonged bone marrow dysfunction or any condition associated with aplastic anemia. None had had evidence of aplastic anemia before the procedure, although all had received infusions of blood products before surgery. The absolute neutrophil count determined before trans-394 THE :-;'EW ENGLAND JOUR.NAL OF MEDICINE Five patients are alive at this writing. Patient 1 received four transplants. The first failed because of primary nonfunction, and the second and third because of graft rejection. The patient is alive and has normal peripheral-blood counts 24 months after receiving the fourth transplant. Patient 2, at 12 months after transplantation, has had partial recovery, with a peripheraltAlanine aminmransferase: to convert to microkatals per liter. multiply by 0.01667.
IAbsolute neutrophil count «800 = low).
plantation ranged from 1240 to 5230 per cubic millimeter, and the hematocrit from 28.1 to 37.3 percent. Thrombocytopenia occurred in three patients; in two patients (No.2 and 6) it could not be explained, and in the third (Patient 9) it was associated with a course of acyclovir given because of exposure to chickenpox. A bone marrow examination performed before transplantation showed normal results in one patient (No. 8), and an examination performed five days after transplantation because of transient thrombocytopenia demonstrated increased megakaryocytes in another patient (No.6) ( Table 2 ).
The onset of aplastic anemia occurred 3 to 22 weeks after the onset of hepatitis and 1 to 7 weeks after transplantation (Table 2) . Normal blood counts had been documented in all patients in the interval after transplantation. These patients received various medications before the onset of aplastic anemia, and the majority had received drugs with potential toxicity to bone marrow. However, the pattern of administration and the variety of drugs that they received were in no way unusual for transplant recipients in these centers. Bone marrow cultures -first obtained after the onset of aplastic anemia in seven patients, before transplantation in one, and in the interval between transplantation and the onset of aplastic anemia in one -were negative in all cases.
The treatment of the patients and their outcomes are shown in Table 3 . The general strategy emploved hy all the centers was to withhold any medications that might have contributed to bone marrow dysfunction. Immunosuppression was discontinued or reduced -in principle. to reduce the risk of infection.
Three patients iNa. t, 2, and 6) had alJograft rejection. which necessitated repeat transplantation in one. Table 4 shows the total experience of the participating centers with respect to the occurrence of aplastic anemia after liver transplantation. Aplastic anemia has occurred only after transplantation for non-A, non-B hepatitis, with a frequency of 28 percent. The probability that this observation is due to chance is minute (chi-square = 415, P<O.OOI). The 95 percent confidence interval for the frequency of occurrence of aplastic anemia after liver transplantation for non-A, non-B hepatitis is 13 to 44 percent, as opposed to 0.00 to 0.13 percent for all other indications, assuming the occurrence of half a case in order to do the computation. 9 
DISCUSSION
We found an extremely high frequency of occurrence (28 percent) of aplastic anemia after liver transplantation was performed for the indication of acute non-A, non-B hepatitis. This frequency is in contrast to the absence of this complication among the 1463 patients in the four cooperating centers who received liver transplants for all other indications, the frequency of 0.1 to 0.2 percent reported among patients with acute viral hepatitis who did not undergo transplantation,10-12 and the incidence of 2 to 5 per million per year in the general population:",6 / Non-A, non-B hepatitis is the most frequently diagnosed cause of acute hepatic failure due to hepatitis in our centers, accounting for 58 percent of cases. (As Table 4 shows, most cases of liver failure are not due to hepatitis.) Although several patients in the series had percutaneous exposure to hepatitis -through a transfusion. for example, or a needle stick -none of those who had aplastic anemia did. Sporadic nOli-A, non-B hepatitis remains a poorly defined entity. diagnosed when the patient appears to have viral hnatitis and serologic testing is negative for known agenls. It is necessarily a diagnosis of exclusion, which requires an APLASTIC ANEMIA AFTER LIVER TRANSPLANTATION -TZAKIS ET AL. 39,'j Cyclosporine, conicosteroid. celotaxlme, cimelidine, captopril exhaustive search for other causes. 13 Non-A, non-B hepatitis is not rare, and seems to be more severe than hepatitis A or B. In one series, it accounted for 25 percent of the cases of fulminant viral hepatitis ·in which Grade IV encephalopathy developed among 453 patients with acute hepatic failure. H In other series, it was the diagnosis in 26 of 31 children with fulminant hepatitis 15 and in 32 of 73 young adults with fulminant viral hepatitis.16 Its mortality rate is the highest among the rates for all causes of acute liver failure, which accounts for its frequency among patients referred to our centers for transplantation, In our experience, the only patients in whom aplastic anemia developed after liver transplantation had sporadic non-A, non-B hepatitis, Few data have been reported on the occurrence of aplastic anemia among patients with non-A, non-B hepatitis and acute hepatic failure, perhaps because few patients survive long In another series, of 31 children with fulminant hepatic failure, 2 had aplastic anemia and 2 others had prolonged t!lrombocytopenia; all these patients had sporadic non~A, non-B hepatitis. IS The frequency,of the occurrence of aplastic anerriia in our series is higher than in any previous report. It seems possible that successful transplantation simply permitted the frequerit e.xpression of aplastic anemia, which was precluded by a death rate that approached 90 percent in other s'eriesY Furthermore, it cari be concluded that aplastic anemia is not a complication of liver failure. It was not a complication of the course in other patients with equal degrees of hepatic compromise, and in the majority of patients described here, liver function was normal when aplastic anemia became evident, We could not discern any differences in the technique of transplantation, the drugs used in the postoperative period, or the types or severity of complications that distinguish these patients.
The high mortality rate ascribed to hepatitis-associated aplastic anemia S ,6,1 i,20 has not been observed in our patients, but the follow-up period has been short. With longer observation, a better assessment can be made of the effect of this complication on survival and the need for intervention with therapies such as bone marrow transplantation.
